TTN mutation has been correlated with longer progression-free survival and response to immune checkpoint receptor blockade therapy in solid tumors [54] and is also reported to predict a poor prognosis in patients with thyroid cancer [55]. This evidence concerns the gene TTN and thyroid cancer.